Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.
Also called NCT01541943
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 356 participants
- Sponsor
- HanAll BioPharma Co., Ltd.
- Registry
-
NCT01541943
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01541943. Randomized; double masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2014-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
- Condition
- Essential Hypertension
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- HL-040XC
- Lead sponsor
- HanAll BioPharma Co., Ltd.
Record details
- Record id
cardio:ct-nct01541943- Content hash
0b62b36c7a3373f39b90b7ba7be2adea71e22c789e3d63ca21e36234c23759b8